Relmada Therapeutics Inc (NQ: RLMD )
2.770
-0.030
(-1.07%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Press Releases about Relmada Therapeutics Inc
![](https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg)
![](https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg)
![](https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg)
![](https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg)
![](https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg)
![](https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg)
![](https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg)
![](https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg)
![](https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg)
![](https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg)
![](https://ml.globenewswire.com/media/745335af-3a3a-4fb5-84c0-fdedc9adf092/small/july-30-2021-rosen-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg)
![](https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg)
![](https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg)
Via SBWire
![](https://mms.businesswire.com/media/20230511005665/en/779279/5/Screen_Shot_2020-03-10_at_10.22.21_AM.jpg)
![](https://mms.businesswire.com/media/20230509006097/en/538768/22/BES_Mark.jpg)
![](https://mms.businesswire.com/media/20230501005696/en/1164042/5/July_30%2C_2021_-_ROSEN_LOGO.jpg)
![](https://mms.businesswire.com/media/20230427005632/en/827144/22/Schall-Firm-Logo-640x360.jpg)
![](https://mms.businesswire.com/media/20230426006040/en/827144/22/Schall-Firm-Logo-640x360.jpg)
Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028
May 26, 2022
Exposures
COVID-19
Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally
February 24, 2022
Exposures
COVID-19
Intranasal Ketamine Garnering A lot of Attention as an Effective Treatment For Depression
November 23, 2021
Exposures
COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.